IgG multiple myeloma presented with ulcerative pyoderma gangrenosum

Verrou, Evgenia; Kartsios, Charalambos; Banti, Anastasia; Mihou, Dimitra; Kaloutsi, V.; Lazaridou, Anna; Zervas, Konstantinos

doi:10.1080/10428190701361224

Cited by 8 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between PG and myeloma and/or paraproteinaemia has been widely reported 5,6 . As in the present case, PG may precede the development of myeloma by a few years, and treatment of the myeloma may produce improvement in the PG lesions 6 …”

Section: Reportsupporting

confidence: 72%

See 1 more Smart Citation

Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum

Shareef

Munro

Owen

et al. 2011

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.

show abstract

Section: Reportsupporting

confidence: 72%

“…5,6 As in the present case, PG may precede the development of myeloma by a few years, and treatment of the myeloma may produce improvement in the PG lesions. 6 Treating PG can be difficult. The best-established agents are systemic steroids and ciclosporin, but the response is variable, and the doses required to control the disease may be toxic.…”

supporting

confidence: 57%

Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum

Shareef

Munro

Owen

et al. 2011

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…However, the relationship between MM and PG is unclear 9 10. It seems that PG is most commonly associated with monoclonal gammopathy, and it has been detected in 10%–20% of PG cases 9. IgA is the paraprotein in the majority of cases 9–13.…”

Section: Discussionmentioning

confidence: 99%

Postsurgical pyoderma gangrenosum after an autologous stem cell transplantation for multiple myeloma

Bittencourt

Atanazio²,

Xavier

et al. 2018

BMJ Case Reports

View full text Add to dashboard Cite

We report a man who underwent autologous stem cell transplantation (ASCT) for multiple myeloma. Two months after ASCT, he presented with necrotising cholecystitis due to gallbladder stones and was submitted to laparoscopic cholecystectomy. About a week later, he developed progressive skin ulcers at sites where trochanters had been inserted. Progressive enlargement and necrotic aspect of these ulcers took place despite debridement and large spectrum antibiotics. New ulcers developed at the site of enoxaparin injection at the right arm (pathergy phenomenon). A skin biopsy and clinical evaluation favoured the diagnosis of pyoderma gangrenosum (PG). He was treated with daily methylprednisolone and dapsone with improvement of the lesions. This is the first case in the literature of PG after ASCT. Despite the risk factors, the onset of an autoinflammatory disease right after the transplant is intriguing since PG is extremely rare in immunocompromised patients.

show abstract

“…In almost all cases, pyoderma gangrenosum either preceded or was diagnosed concurrently with the plasma cell dyscrasia. 3–5 The skin lesions resolved after successful myeloma therapy and its clinico-laboratory remission. 4,5 Given the association between pyoderma gangrenosum and plasma cell dyscrasias, clinicians of various specialties should perhaps order at least serum protein electrophoresis in patients with pyoderma gangrenosum and no known primary systemic disorder.…”

Section: Discussionmentioning

confidence: 99%

Pyoderma gangrenosum due to lenalidomide use for multiple myeloma

Dasanu

Bockorny

Alexandrescu

2014

J Oncol Pharm Pract

View full text Add to dashboard Cite

Pyoderma gangrenosum has been described in association with multiple myeloma and usually affects patients with active/untreated disease. This dermatologic condition was shown to resolve after successful anti-myeloma therapy. We report herein occurrence of pyoderma gangrenosum involving bilateral knees in a patient with multiple myeloma responding to lenalidomide therapy. Previous papers claimed usefulness of thalidomide and its newer derivatives for the therapy of this neutrophilic dermatosis. Occurrence of pyoderma gangrenosum in a myeloma patient responding to lenalidomide would argue against its effectiveness in treating this skin condition. Moreover, the clinical setting suggested that lenalidomide either induced or contributed to the occurrence of pyoderma gangrenosum in our patient. If our hypothesis is correct, we expect more reports of pyoderma gangrenosum with the use of this class of pharmaceuticals.

show abstract

IgG multiple myeloma presented with ulcerative pyoderma gangrenosum

Cited by 8 publications

References 13 publications

Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum

Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum

Postsurgical pyoderma gangrenosum after an autologous stem cell transplantation for multiple myeloma

Pyoderma gangrenosum due to lenalidomide use for multiple myeloma

Contact Info

Product

Resources

About